{"id":"NCT04402489","sponsor":"Mitsubishi Tanabe Pharma America Inc.","briefTitle":"Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-06-01","primaryCompletion":"2021-12-14","completion":"2022-07-26","firstPosted":"2020-05-26","resultsPosted":"2025-03-21","lastUpdate":"2025-03-21"},"enrollment":184,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["EPP","XLP"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"MT-7117 Low Dose","otherNames":["Dersimelagon"]},{"type":"DRUG","name":"MT-7117 High Dose","otherNames":["Dersimelagon"]}],"arms":[{"label":"Placebo Comparator","type":"PLACEBO_COMPARATOR"},{"label":"MT-7117 Low Dose","type":"EXPERIMENTAL"},{"label":"MT-7117 High Dose","type":"EXPERIMENTAL"}],"summary":"The primary objective of this study is to investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP aged 12-75.","primaryOutcome":{"measure":"Change From Baseline in Average Daily Sunlight Exposure Time (Minutes) to First Prodromal Symptom (Burning, Tingling, Itching, or Stinging) Associated With Sunlight Exposure Between 1 Hour Post Sunrise and 1 Hour Pre-sunset at Week 26 (Visit 7)","timeFrame":"From 1 hour post-sunrise to 1 hour pre-sunset at Week 26 (Visit 7)","effectByArm":[{"arm":"DBT ITT1 Placebo","deltaMin":20.59,"sd":10.29},{"arm":"DBT ITT1 MT- 7117 Low Dose","deltaMin":30.39,"sd":10.04},{"arm":"DBT ITT1 MT- 7117 High Dose","deltaMin":43.29,"sd":10.13}],"pValues":[{"comp":"OG000 vs OG001","p":"0.496"},{"comp":"OG000 vs OG002","p":"0.116"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":31,"countries":["United States","Australia","Canada","Germany","Italy","Japan","Norway","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["39887900"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":61},"commonTop":["COVID-19","Nausea","Headache","Melanocytic naevus","Skin hyperpigmentation"]}}